Ipsen and its fellow French partner Genfit are competing with Intercept and Advanz’s Ocaliva, which was approved in 2016 and ...

The FDA in 2016 granted accelerated approval to the farnesoid X receptor (FXR) agonist as a second-line treatment for adults with PBC, either in combination with ursodeoxycholic acid (UDCA ...

Compared to endogenous intestinal FXR antagonist GUDCA and FXR agonist OCA, DC646 exhibited superior efficacy in alleviating hepatic lipid metabolism disorders, inflammation, and fibrosis.

Therapeutic advancements have already begun to show promise. FXR agonists such as obeticholic acid (OCA) have demonstrated potential in reducing liver lipid accumulation and inflammation ...

The development of TGR5 agonists could have benefits to combat many aspects of the metabolic syndrome, whereas FXR-α agonists could hold promise for reducing hypertriglyceridaemia and modulating ...

Osteoarthritis (OA) is one of the most prevalent conditions affecting tens of millions of U.S. adults, traditionally ...

The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was ...